# RhythmScience

> RhythmScience sells Rhythm360, a vendor-neutral cardiac data platform and optional monitoring services for cardiology practices and health systems. It combines transmissions from implanted devices, wearables and home sensors with triage, reporting, EHR integration and patient outreach. A University of Chicago Medicine account of its use makes the practical case: the hard part of remote monitoring is managing the large volume of routine signals so clinicians can reach the consequential ones.

- **Founded:** 2019
- **Headquarters:** San Francisco, United States
- **Founders:** Shawn Kumar (Founder and CEO)
- **Products:** Rhythm360, Remote technical and patient engagement services, Rhythm360 for Providers, Cedars-Sinai HF-AI license
- **Notable:** University of Chicago Medicine reviewed more than 73,000 Rhythm360 reports during 2025, according to a 2026 RhythmScience-sponsored white paper., Closed a $6 million Series A led by Cedars-Sinai Health Ventures in March 2023., Added support for CVRx Barostim and Impulse Dynamics Optimizer Smart Mini heart-failure therapies in 2024.

## Products & services

- **Rhythm360** — Cloud platform that brings implantable cardiac devices, ambulatory monitors, wearables and remote physiologic sensors into a shared review, reporting and billing workflow.
- **Remote technical and patient engagement services** — Optional trained personnel for first-level review, reporting support, transmission compliance, patient outreach and coaching.
- **Rhythm360 for Providers** — Mobile application for clinical review, notation and report sign-off.
- **Cedars-Sinai HF-AI license** — Exclusive rights announced for an algorithm designed to support guideline-directed medical therapy in heart failure; the announcement described planned integration with Rhythm360.

## Achievements

- University of Chicago Medicine reviewed more than 73,000 Rhythm360 reports during 2025, according to a 2026 RhythmScience-sponsored white paper.
- Closed a $6 million Series A led by Cedars-Sinai Health Ventures in March 2023.
- Added support for CVRx Barostim and Impulse Dynamics Optimizer Smart Mini heart-failure therapies in 2024.
- Licensed exclusive rights to a Cedars-Sinai heart-failure AI algorithm in September 2025.

## Latest updates

- **2026-04** — A RhythmScience-sponsored EP Lab Digest white paper described University of Chicago Medicine's 2025 monitoring workflow and more than 73,000 reports reviewed.
- **2025-09** — Announced an exclusive license to a Cedars-Sinai heart-failure AI algorithm.
- **2024-11** — Announced integration of CVRx Barostim and Impulse Dynamics Optimizer Smart Mini data.

## Links

- Website: https://www.rhythm360.io/
- LinkedIn: https://www.linkedin.com/company/rhythmscience
- Twitter/X: https://twitter.com/rhythmsci
- Facebook: https://www.facebook.com/RhythmScienceInc

---

Profile page: https://yespress.io/rhythmscience
Published by YesPress — https://yespress.io
Last updated: 2026-09-29